Clinical Trial Update: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety and immune response data for dolutegravir in HIV-1 infected infants, children, and adolescents from Phase 1 and Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-03-22